Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona

Translated title of the contribution: Drug resistance of Mycobacterium tuberculosis. Multicenter study in Barcelona, Spain

Nuria Martín-Casabona, Fernando Alcaide, Pere Coll, Julià González, José M. Manterola, Margarita Salvadó, Juan A. Caylà

Research output: Contribution to journalArticle

Abstract

Background: The aim of this multicenter study was to establish the level of primary and acquired drug resistance of M. tuberculosis strains isolated in Barcelona and to identify possible risk groups using clinical data. PATIENTS AND METHOD: All tuberculosis patients with isolation and identification of M. tuberculosis strains from October 1995 to September 1997 were included. Susceptibility tests against isoniazid, rifampin, ethambutol, streptomycin and pyrazinamide were performed using the Bactec 460 system and the proportions method on solid medium. Logistic progression was used for statistical analysis. RESULTS: The total number of patients included was 1,749 (1,535 non-treated and 214 previously treated). Primary drug resistance was 5.7% (isoniazid 3.8%; rifampin 1.0%, streptomycin 2.1%, ethambutol 0.3% and pyrazinamide 1.0%). Acquired drug resistance was 20.5% (isoniazid 17.3%; rifampin 9.8%, ethambutol 1.9%, streptomycin 4.7% and pyrazinamide 6.5%). Primary drug resistance against isoniazid and pyrazinamide were associated with foreign people. The total acquired drug resistance was associated with people over 60 years old and women. CONCLUSIONS: The low level of primary drug resistance enables antituberculosis treatment of non-treated patients to start with the standardised three-drug regimes except in the case of foreign people from countries with a high level of drug resistance. Susceptibility tests are recommended on all M. tuberculosis strains isolated, together with controlled studies of drug resistance surveillance.

Original languageSpanish
Pages (from-to)493-498
Number of pages6
JournalMedicina clínica
Volume115
Issue number13
StatePublished - Oct 21 2000
Externally publishedYes

Fingerprint

Mycobacterium tuberculosis
Drug Resistance
Spain
Multicenter Studies
Pyrazinamide
Isoniazid
Ethambutol
Streptomycin
Rifampin
Patient Isolation
Tuberculosis
Pharmaceutical Preparations

Keywords

  • Acquired drug resistance
  • Multidrug resistance
  • Primary drug resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Martín-Casabona, N., Alcaide, F., Coll, P., González, J., Manterola, J. M., Salvadó, M., & Caylà, J. A. (2000). Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Medicina clínica, 115(13), 493-498.

Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. / Martín-Casabona, Nuria; Alcaide, Fernando; Coll, Pere; González, Julià; Manterola, José M.; Salvadó, Margarita; Caylà, Juan A.

In: Medicina clínica, Vol. 115, No. 13, 21.10.2000, p. 493-498.

Research output: Contribution to journalArticle

Martín-Casabona, N, Alcaide, F, Coll, P, González, J, Manterola, JM, Salvadó, M & Caylà, JA 2000, 'Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona', Medicina clínica, vol. 115, no. 13, pp. 493-498.
Martín-Casabona N, Alcaide F, Coll P, González J, Manterola JM, Salvadó M et al. Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Medicina clínica. 2000 Oct 21;115(13):493-498.
Martín-Casabona, Nuria ; Alcaide, Fernando ; Coll, Pere ; González, Julià ; Manterola, José M. ; Salvadó, Margarita ; Caylà, Juan A. / Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. In: Medicina clínica. 2000 ; Vol. 115, No. 13. pp. 493-498.
@article{67cf468060b145b683d754272177880d,
title = "Farmacorresistencia de Mycobacterium tuberculosis. Estudio multic{\'e}ntrico en el {\'a}rea de Barcelona",
abstract = "Background: The aim of this multicenter study was to establish the level of primary and acquired drug resistance of M. tuberculosis strains isolated in Barcelona and to identify possible risk groups using clinical data. PATIENTS AND METHOD: All tuberculosis patients with isolation and identification of M. tuberculosis strains from October 1995 to September 1997 were included. Susceptibility tests against isoniazid, rifampin, ethambutol, streptomycin and pyrazinamide were performed using the Bactec 460 system and the proportions method on solid medium. Logistic progression was used for statistical analysis. RESULTS: The total number of patients included was 1,749 (1,535 non-treated and 214 previously treated). Primary drug resistance was 5.7{\%} (isoniazid 3.8{\%}; rifampin 1.0{\%}, streptomycin 2.1{\%}, ethambutol 0.3{\%} and pyrazinamide 1.0{\%}). Acquired drug resistance was 20.5{\%} (isoniazid 17.3{\%}; rifampin 9.8{\%}, ethambutol 1.9{\%}, streptomycin 4.7{\%} and pyrazinamide 6.5{\%}). Primary drug resistance against isoniazid and pyrazinamide were associated with foreign people. The total acquired drug resistance was associated with people over 60 years old and women. CONCLUSIONS: The low level of primary drug resistance enables antituberculosis treatment of non-treated patients to start with the standardised three-drug regimes except in the case of foreign people from countries with a high level of drug resistance. Susceptibility tests are recommended on all M. tuberculosis strains isolated, together with controlled studies of drug resistance surveillance.",
keywords = "Acquired drug resistance, Multidrug resistance, Primary drug resistance, Tuberculosis",
author = "Nuria Mart{\'i}n-Casabona and Fernando Alcaide and Pere Coll and Juli{\`a} Gonz{\'a}lez and Manterola, {Jos{\'e} M.} and Margarita Salvad{\'o} and Cayl{\`a}, {Juan A.}",
year = "2000",
month = "10",
day = "21",
language = "Spanish",
volume = "115",
pages = "493--498",
journal = "Medicina Clinica",
issn = "0025-7753",
publisher = "Ediciones Doyma, S.L.",
number = "13",

}

TY - JOUR

T1 - Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona

AU - Martín-Casabona, Nuria

AU - Alcaide, Fernando

AU - Coll, Pere

AU - González, Julià

AU - Manterola, José M.

AU - Salvadó, Margarita

AU - Caylà, Juan A.

PY - 2000/10/21

Y1 - 2000/10/21

N2 - Background: The aim of this multicenter study was to establish the level of primary and acquired drug resistance of M. tuberculosis strains isolated in Barcelona and to identify possible risk groups using clinical data. PATIENTS AND METHOD: All tuberculosis patients with isolation and identification of M. tuberculosis strains from October 1995 to September 1997 were included. Susceptibility tests against isoniazid, rifampin, ethambutol, streptomycin and pyrazinamide were performed using the Bactec 460 system and the proportions method on solid medium. Logistic progression was used for statistical analysis. RESULTS: The total number of patients included was 1,749 (1,535 non-treated and 214 previously treated). Primary drug resistance was 5.7% (isoniazid 3.8%; rifampin 1.0%, streptomycin 2.1%, ethambutol 0.3% and pyrazinamide 1.0%). Acquired drug resistance was 20.5% (isoniazid 17.3%; rifampin 9.8%, ethambutol 1.9%, streptomycin 4.7% and pyrazinamide 6.5%). Primary drug resistance against isoniazid and pyrazinamide were associated with foreign people. The total acquired drug resistance was associated with people over 60 years old and women. CONCLUSIONS: The low level of primary drug resistance enables antituberculosis treatment of non-treated patients to start with the standardised three-drug regimes except in the case of foreign people from countries with a high level of drug resistance. Susceptibility tests are recommended on all M. tuberculosis strains isolated, together with controlled studies of drug resistance surveillance.

AB - Background: The aim of this multicenter study was to establish the level of primary and acquired drug resistance of M. tuberculosis strains isolated in Barcelona and to identify possible risk groups using clinical data. PATIENTS AND METHOD: All tuberculosis patients with isolation and identification of M. tuberculosis strains from October 1995 to September 1997 were included. Susceptibility tests against isoniazid, rifampin, ethambutol, streptomycin and pyrazinamide were performed using the Bactec 460 system and the proportions method on solid medium. Logistic progression was used for statistical analysis. RESULTS: The total number of patients included was 1,749 (1,535 non-treated and 214 previously treated). Primary drug resistance was 5.7% (isoniazid 3.8%; rifampin 1.0%, streptomycin 2.1%, ethambutol 0.3% and pyrazinamide 1.0%). Acquired drug resistance was 20.5% (isoniazid 17.3%; rifampin 9.8%, ethambutol 1.9%, streptomycin 4.7% and pyrazinamide 6.5%). Primary drug resistance against isoniazid and pyrazinamide were associated with foreign people. The total acquired drug resistance was associated with people over 60 years old and women. CONCLUSIONS: The low level of primary drug resistance enables antituberculosis treatment of non-treated patients to start with the standardised three-drug regimes except in the case of foreign people from countries with a high level of drug resistance. Susceptibility tests are recommended on all M. tuberculosis strains isolated, together with controlled studies of drug resistance surveillance.

KW - Acquired drug resistance

KW - Multidrug resistance

KW - Primary drug resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0342935983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342935983&partnerID=8YFLogxK

M3 - Article

C2 - 11386223

AN - SCOPUS:0342935983

VL - 115

SP - 493

EP - 498

JO - Medicina Clinica

JF - Medicina Clinica

SN - 0025-7753

IS - 13

ER -